about
Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.Comparative biochemical studies of fresh frozen plasma and pooled solvent/detergent-treated plasma (octaplasLG® ) with focus on protein S and its impact in different thrombin generation assay set-ups.Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.Bleeding and thrombotic complications of pediatric liver transplant.
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Global haemostasis and point of care testing.
@en
Global haemostasis and point of care testing.
@nl
type
label
Global haemostasis and point of care testing.
@en
Global haemostasis and point of care testing.
@nl
prefLabel
Global haemostasis and point of care testing.
@en
Global haemostasis and point of care testing.
@nl
P2093
P2860
P1433
P1476
Global haemostasis and point of care testing
@en
P2093
P2860
P356
10.1111/J.1365-2516.2012.02855.X
P478
18 Suppl 4
P577
2012-07-01T00:00:00Z